DASH vs RPRX · P/E 76, rev $8.49B vs P/E 15, rev $1.30B
DoorDash, Inc. Class A Common Stock (DASH) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported DASH revenue for 2026-06-30 was $8.49B. Net income was $384.0M. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the DASH and RPRX stock pages for the full models.
Not investment advice.